Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAnpario Regulatory News (ANP)

Share Price Information for Anpario (ANP)

Share Price is delayed by 15 minutes
Get Live Data
520.00    5.00 (0.97%)
Bid:
510.00
Ask:
530.00
Spread: 20.00 (3.922%)
Market Cap: £85.47m
ANP Live PriceLast checked at - London Stock Exchange

Intraday Anpario Share Chart

Full year trading statement

10 Jan 2025 07:00

RNS Number : 8294S
Anpario PLC
10 January 2025
 

THIS ANNOUNCEMENT RELATES TO THE DISCLOSURE OF INFORMATION THAT QUALIFIED OR MAY HAVE QUALIFIED AS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018.

 

 

Anpario plc("Anpario", the "Group" or the "Company")

 

Full year trading statement

 

Anpario plc (AIM:ANP), the independent manufacturer of natural sustainable animal feed additives for health, nutrition and biosecurity, provides the following trading update for the year ended 31 December 2024 ("FY 2024"). The figures set out in this announcement remain subject to audit.

 

Trading update

The Group, including three months of trading for Bio-Vet Inc., delivered a stronger than expected operating performance in the second half of 2024. Year-end sales were higher than anticipated, and the Group now expects revenue for the 12 months ended 31 December 2024 to be approximately £37.5m* (31 December 2023: £31.0m). This strong performance in revenue combined with the Group's high operational gearing and favourable year-end foreign exchange movements, will result in adjusted EBITDA being ahead of current market expectations*.

 

Bio-Vet Inc. had a strong final quarter due to heightened demand for its products, which support the health of dairy cows affected by avian influenza, and our Middle East and Africa segment delivered an outstanding sales performance.

 

Financial position

Our financial position remains strong, with year-end cash balances of £10.5m* (31 December 2023: £10.6m), after accounting for the acquisition of Bio-Vet Inc. and associated land and buildings for an initial cash consideration of US$6.3m, on a debt-free basis, which completed in September 2024.

 

Our strong balance sheet enables the Group to invest in innovative natural product solutions, expand our global reach and explore earnings enhancing and complementary acquisitions to continue the profitable development of the Group. We remain confident in our ability to capitalise on growth opportunities, delivering long-term benefits to all stakeholders.

 

FY2024 Results

The Group expects to publish its FY 2024 final results on or around 26 March 2025.

 

 

 

*Analyst consensus for FY 2024 immediately prior to this announcement was Revenue of £35.25m, EBITDA of £5.7m and net cash of £7.2m.

 

Enquiries

 

Anpario plc

Richard Edwards, Chief Executive Officer

+44(0)7776 417 129

Marc Wilson, Group Finance Director

+44(0)1909 537 380

Shore Capital

 

(Nominated Adviser and Broker)

+44 (0) 20 7408 4090

Stephane Auton

Corporate Advisory

David Coaten

Tom Knibbs

Henry Willcocks

Corporate Broking

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTUPUUUGUPAPWB
Date   Source Headline
17th Mar 20217:00 amRNSFinal Results
15th Mar 20213:38 pmRNSDirector/PDMR Shareholding
12th Mar 20217:00 amRNSDirectorate Change
4th Feb 20212:54 pmRNSBlock Listing Application
3rd Feb 20214:52 pmRNSDirector/PDMR Shareholding
3rd Feb 20214:30 pmRNSTotal Voting Rights
26th Jan 20217:00 amRNSTrading Statement and Board update
25th Jan 20217:00 amRNSDirectorate Change
18th Jan 20217:00 amBUSBlock listing Interim Review
8th Jan 20217:00 amBUSDirectorate change
9th Dec 202010:55 amBUSTotal Voting Rights
5th Nov 20205:03 pmBUSDirector/PDMR Shareholding
3rd Nov 202010:06 amRNSTotal Voting Rights
16th Oct 20201:22 pmRNSLady Oregon Goes Aloft
9th Oct 20207:17 amRNSDirector/PDMR Shareholding
2nd Oct 202012:13 pmRNSTotal Voting Rights
24th Sep 20207:00 amRNSChange of auditor
18th Sep 20204:24 pmRNSDirector/PDMR Shareholding
9th Sep 20207:00 amBUSHalf-year Report
17th Jul 202010:55 amRNSBlock listing Interim Review
7th Jul 20201:43 pmRNSTotal Voting Rights
3rd Jul 20203:42 pmRNSHolding(s) in Company
3rd Jul 20202:42 pmRNSHolding(s) in Company
25th Jun 20202:13 pmRNSResult of the AGM
25th Jun 20207:00 amRNSAGM Statement
18th Jun 20205:06 pmRNSHolding(s) in Company
1st May 20205:43 pmBUSNotice of AGM
1st May 202010:16 amRNSTotal Voting Rights
29th Apr 20207:00 amRNSCOVID-19 Update and Patent Application
7th Apr 20208:45 amRNSTotal Voting Rights
18th Mar 20207:00 amBUSFinal Results
13th Mar 20207:00 amRNSTransaction in Own Shares
13th Mar 20207:00 amRNSCompletion of Buyback Programme
12th Mar 20207:00 amRNSTransaction in Own Shares
11th Mar 20207:00 amRNSTransaction in Own Shares
10th Mar 20207:00 amRNSTransaction in Own Shares
9th Mar 20207:00 amRNSTransaction in Own Shares
3rd Mar 20207:00 amRNSTransaction in Own Shares
2nd Mar 20207:00 amRNSTransaction in Own Shares
25th Feb 20207:00 amRNSTransaction in Own Shares
24th Feb 20207:00 amRNSTransaction in Own Shares
20th Feb 20203:11 pmRNSHolding(s) in Company
17th Feb 20207:00 amRNSTransaction in Own Shares
12th Feb 20207:00 amRNSTransaction in Own Shares
7th Feb 20203:31 pmRNSHolding(s) in Company
7th Feb 202011:16 amRNSHolding(s) in Company
7th Feb 20207:00 amRNSTransaction in Own Shares
5th Feb 20205:14 pmRNSShare Buyback Programme
5th Feb 20209:00 amRNSDirector/PDMR Shareholding
30th Jan 20203:51 pmRNSBlock Listing Application

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.